Findings

What do systematic reviews say?

67 questions · 67 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 19.4%GRADE not reported 14 · 20.9%Very low 20 · 29.9%Low 9 · 13.4%Moderate 11 · 16.4%High 0 · 0%

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Drug‐related AE: serum creatinine increased (≥ 33%) above baseline in 2 consecutive occasions · people with transfusion‐dependent thalassemia

It is very uncertain whether deferasirox and deferiprone changes drug‐related AE: serum creatinine increased (≥ 33%) above baseline… compared with deferiprone and deferoxamine (very low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 3 [0.32, 27.83]
1 study · 96 participants
Very low

Deferasirox and deferoxamine vs deferoxamine

Mortality at any time point · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Low

Deferasirox and deferoxamine vs deferoxamine

Responder analysis · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox and deferoxamine vs deferoxamine

Serum ferritin (ng/mL) · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low

Deferasirox and deferoxamine vs deferoxamine

LIC · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox and deferoxamine vs deferoxamine

Satisfaction with treatment · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox and deferoxamine vs deferoxamine

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low

Deferasirox and deferoxamine vs deferoxamine

AE: Serum creatinine increase · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combined deferasirox and deferiprone vs deferiprone

Mortality at any time point · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Combined deferasirox and deferiprone vs deferiprone

Responder analysis · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Combined deferasirox and deferiprone vs deferiprone

Serum ferritin (ng/mL) · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Combined deferasirox and deferiprone vs deferiprone

LIC · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Combined deferasirox and deferiprone vs deferiprone

Satisfaction with treatment · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Combined deferasirox and deferiprone vs deferiprone

Adherence · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Combined deferasirox and deferiprone vs deferiprone

AE: Serum creatinine increase · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs deferiprone (DFO)

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

Adherence to iron chelation therapy (%, SD)

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 452 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ thalassaemia‐related SAEs

It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low